A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
PMV Pharmaceuticals, Inc
PMV Pharmaceuticals, Inc
Genentech, Inc.
Combined Military Hospital Gujranwala
AstraZeneca
Jinnah Postgraduate Medical Centre
City of Hope Medical Center
University of Arkansas
Barbara Ann Karmanos Cancer Institute
University of Toledo
Thomas Jefferson University
M.D. Anderson Cancer Center
University of Pittsburgh
University of California, Davis
Turning Point Therapeutics, Inc.
M.D. Anderson Cancer Center
University of Alberta
Mayo Clinic
University Medical Center Groningen
Zagazig University
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Columbia University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
City of Hope Medical Center
Beni-Suef University
National Institutes of Health Clinical Center (CC)
Jiangsu HengRui Medicine Co., Ltd.
University of Cincinnati
Fox Chase Cancer Center
Northwestern University
Medical University of South Carolina
Sheba Medical Center
Columbia University
H. Lee Moffitt Cancer Center and Research Institute
Tufts Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Tufts Medical Center
National Cancer Institute (NCI)